| 发明名称 |
Chimeric NK receptor and methods for treating cancer |
| 摘要 |
The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided. |
| 申请公布号 |
US2015225470(A1) |
申请公布日期 |
2015.08.13 |
| 申请号 |
US201514600799 |
申请日期 |
2015.01.20 |
| 申请人 |
TRUSTEES OF DARTMOUTH COLLEGE ;NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS) |
发明人 |
Zhang Tong;Sentman Charles L. |
| 分类号 |
C07K14/705;A61K45/06;A61K35/17 |
主分类号 |
C07K14/705 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A nucleic acid construct for expressing a chimeric receptor to reduce or eliminate a tumor comprising:
a first nucleic acid sequence encoding a promoter operably linked to a second nucleic acid sequence encoding a chimeric receptor comprising a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif of SEQ ID NO:1. |
| 地址 |
HANOVER NH US |
